Less than a quarter of patients with severe to very severe COPD are likely to respond to inhaled corticosteroid therapy, a post hoc analysis of the WISDOM trial of ICS withdrawal has concluded. Presented as a poster at ATS, and also published in Lancet Respiratory Medicine, the analysis found that withdrawal of ICS did increase ...
Minority of COPD patients benefit from steroids: WISDOM analysis
Sponsored by Boehringer Ingelheim Pty Ltd
24 May 2016